Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 614 participants.

Also called NCT06648304

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 614 participants (enrolled count) (from the registry)
Sponsor
Shanghai Auzone Biological Technology Co., Ltd. (from the registry)
Registry
  • NCT NCT06648304
Other papers using this trial's data
  • Early and prolonged oral edaravone for neuroprotection in acute ischemic stroke: the ERASE-STROKE randomized controlled phase 3 trial Science bulletin, 2026-09-30 DOI, PubMed 42705987

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06648304. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-25 (actual); primary completion 2024-06-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
TTYP01 tablets
Intervention (Drug)
Placebo (Simulant TTYP01 Tablets)
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06648304
Content hash
ed15ecff0b4d02b8fad0f4baab88bc4bdb622380971c6c4eee20960b9dbef7bf